{"cik":1750149,"taxonomy":"us-gaap","tag":"LongTermDebt","label":"Long-term Debt","description":"Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.","entityName":"Inhibikase Therapeutics, Inc.","units":{"USD":[{"end":"2021-03-31","val":1243700,"accn":"0001564590-21-028436","fy":2021,"fp":"Q1","form":"10-Q","filed":"2021-05-17","frame":"CY2021Q1I"},{"end":"2021-06-30","val":248911,"accn":"0001564590-21-044637","fy":2021,"fp":"Q2","form":"10-Q","filed":"2021-08-16","frame":"CY2021Q2I"},{"end":"2021-09-30","val":248911,"accn":"0000950170-21-004620","fy":2021,"fp":"Q3","form":"10-Q","filed":"2021-11-15","frame":"CY2021Q3I"},{"end":"2021-12-31","val":248911,"accn":"0000950170-22-005203","fy":2021,"fp":"FY","form":"10-K","filed":"2022-03-31","frame":"CY2021Q4I"},{"end":"2023-12-31","val":381784,"accn":"0000950170-24-037160","fy":2023,"fp":"FY","form":"10-K","filed":"2024-03-27","frame":"CY2023Q4I"}]}}